ABL1 and acute lymphoblastic leukemia: Mice transplanted with CDKN2Ako/BCR::ABL1+ B-ALL cells displayed a prolonged survival when treated with a combination of LIMKi and TKIs, indicating that CEL-Amide might be a promising new therapy for BCR::ABL+ ALL [121].